N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=155 Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery
Pain
Primary: Area Under the Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores — 136.431; 254.119 cm*hr — p=<0.0001
Phase 2 N=79 Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)
HIV · HIV Infections
Primary: Percentage of Participants With ≥1 Adverse Events (AEs) — 91 Percentage of Participants
Phase 2 N=102 A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Major Depression
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part A — 92.3 percentage of participants
Phase 2 N=68 Bevacizumab Beyond Progression (BBP)
Malignant Glioma · Grade 4 Malignant Glioma · Glioblastoma
Primary: Overall Survival — 17.8 months
Phase 2 N=100 Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Diarrhea
Primary: Number of Participants With Grade 3/4 Diarrhea — 27; 26; 7; 3 Participants
Phase 2 N=140 Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
Plasmodium Falciparum Infection
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28) — 80.8; 90.3; 90.9…
Phase 3 N=72 Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Type 2 Diabetes
Primary: Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24 — -0.25; 0.50 Percentage of HbA1c — p=0.101
N/A N=6,369 Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
HIV Infections
Primary: Aim 1: Proportion of Adult OPD Clients Tested for HIV — 1951; 1837; 2097 Participants
Early Phase 1 N=219 Gabapentin for Perioperative Pain Relief in Surgical Abortion
Pain Control
Primary: Pain Score — 17; 17 score on a scale
Phase 2 N=275 Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Breast Cancer
Primary: Disease-free Survival (DFS) — 89.8; 83.8 Percentage of participants who survived — p=0.18
Phase 4 N=80 Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.
Anesthetic Effectiveness
Primary: Number of Participants Achieving Pulpal Anesthesia. — 52; 57 Participants
N/A N=100 Cold Plasma for the Reduction of Lymphoceles Following PLND
Lymphoceles Following Pelvic Lymph Node Dissection
Primary: Number of Participants With Incidence of Lymphocele Formation — 1 Participants
N/A N=35 Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
Heart Failure
Primary: To Establish Equivalence Between the Heart Sounds Data Recorded by the LifeVest and FDA-cleared AUDICOR AM System. — 95.88; 96.98; 98.25 ms — p=< 0.001
N/A N=754 Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
Coronary Artery Disease · Coronary Disease · Myocardial Ischemia
Primary: Number of Participants With Clinical Success — 723 Participants